Pfizer and BioNTech Begin Clinical Trial for Omicron-Specific Vaccine
Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday. The study will evaluate the vaccine for safety, tolerability and the level of immune response, as both a primary series and a booster dose, in up to 1,420 healthy adults ages 18 to 55. Awesome!
Photo Credit: Diana Polekhina